Remote video URL
Your peers have not rated this talk yet.
10-minute watch | Talk 1 of 1

ICML: How do we improve outcomes for underserved populations with B-cell malignancies?

Are we ensuring diversity and inclusion in clinical studies?

Dr Mark Bishton
University of Nottingham, Nottingham, UK

Dr Mark Bishop, University of Nottingham, Nottingham, UK, highlights the importance of diversity, equity, and inclusion in clinical trial recruitment, and ways to improve equal participation and diversity in clinical trials

Read more

Talks in this series

10-minute watch | Talk 1 of 1
ICML: How do we improve outcomes for underserved populations with B-cell malignancies?
10-minute watch
ICML: How do we improve outcomes for underserved populations with B-cell malignancies?

Are we ensuring diversity and inclusion in clinical studies?

10-minute watch | Talk 1 of 1
ICML: How do we improve outcomes for underserved populations with B-cell malignancies?
10-minute watch
ICML: How do we improve outcomes for underserved populations with B-cell malignancies?

Are we ensuring diversity and inclusion in clinical studies?

Interested in this topic?

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In the United Kingdom, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.